Drug trial aims to calm overactive immune system in down syndrome
NCT ID NCT04246372
Summary
This study tested whether the drug tofacitinib is safe and effective for treating several common autoimmune skin conditions in adolescents and adults with Down syndrome. Researchers wanted to see if reducing overactive immune signaling could improve skin health, quality of life, and possibly thinking skills. The trial involved 47 participants who took the medication for about five months while their skin conditions and overall health were monitored.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Linda Crnic Institute for Down Syndrome
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.